Optimizing extended-release carbidopa/levodopa in Parkinson disease
暂无分享,去创建一个
W. Ondo | C. Waters | B. Walter | J. Morgan | L. Elmer | A. Espay | K. Klos | R. Dhall | D. Silver | P. Agarwal | F. Pagán
[1] C. Singer,et al. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials , 2015, Journal of Parkinson's disease.
[2] O. Gershanik. Improving l‐dopa therapy: The development of enzyme inhibitors , 2015, Movement disorders : official journal of the Movement Disorder Society.
[3] P. Lewitt,et al. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.
[4] U. Dillmann,et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. , 2014, Parkinsonism & related disorders.
[5] J. Jankovic,et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. , 2014, Parkinsonism & related disorders.
[6] M. Stacy,et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.
[7] W. Poewe,et al. Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease , 2013, European journal of neurology.
[8] L. Metman,et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[9] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[10] Fabrizio Stocchi,et al. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.
[11] M. Hallett,et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[12] D. Nyholm,et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.
[13] H. Lennernäs,et al. Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.
[14] P. Soares-da-Silva,et al. The L-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger. , 2002, European journal of pharmacology.
[15] J. Nutt,et al. The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease , 2001, Clinical neuropharmacology.
[16] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[17] C. Marsden,et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. , 1994, Clinical neuropharmacology.
[18] K C Yeh,et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. , 1989, Neurology.
[19] I. Heuser,et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. , 1989, Neurology.
[20] J. Dobkin,et al. Cerebral vasocapacitance and TIAs , 1989, Neurology.
[21] M. Muenter,et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. , 1988, Mayo Clinic proceedings.
[22] M. Contin,et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. , 1987, Clinical neuropharmacology.
[23] J. Cedarbaum. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs , 1987, Clinical pharmacokinetics.
[24] M. Tomita,et al. Mechanistic analysis for drug permeation through intestinal membrane. , 2007, Drug metabolism and pharmacokinetics.